Skip to content

Inspection Record

Baxalta Belgium Manufacturing S.A. — FDA 483 Findings

US FDAInspected 2019-05-31Published 2026-10-27 3 findingsComplaint and recall handlingDeviation, CAPA, and investigationMaterial and supplier control

View the regulator's official source The source document is always the basis for judgement.

Findings

1Complaint and recall handling

Four non-medical broken vial US complaints for Gammagard Liquid were discovered in April.

2Deviation, CAPA, and investigation

Quality Investigations were not conducted per SOP-2024-Adverse Event Quality Investigations.

3Material and supplier control

There is a failure to thoroughly review a batch or any of its components to meet any of its specifications Whether or not the batch has been already distributed.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-27. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Baxalta Belgium Manufacturing S.A. company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.